Oral treatment for HAE Attacks: Deucrictibant Study
Currently recruiting people with HAE for this trial of a new oral treatment to use for HAE attacks. It works in a similar fashion to Icatibant only there is no injection – it is a capsule that has a quick onset of action.
The following are the criteria:
· People between 12-75 yr with HAE type 1 or 2
· having 2 or more attacks over a 3 month period
· you may be on prophylaxis (Takzhyro;Berinert SC,Danazol, tranexamic acid ) as long as you still experience some attacks
You will have 2 attacks treated within the study-one will be with the new treatment and one will be with placebo or dummy treatment – you will have Icatibant on hand as usual and may use it if you do not feel the oral treatment has been beneficial (rescue medication).
You will need 3 clinic visits and a telehealth appointment and 2 sets of blood tests will be done – one at beginning and one at the end.
You will be asked to fill in a diary and several questionnaires throughout the study
You will be reimbursed for any travel and other expenses you have for participating tin the study
There is the opportunity to go into a follow on or open label study where you will be supplied with the new oral treatment to treat your attacks
We are enrolling now so if interested please contact Pamela Burtom of Prof Connie Katelaris and they will send detailed information and discus your suitability for the study.
Pamela.burton@health.nsw.gov.au or
connie.katelaris@health.nsw.gov.au